Maze Therapeutics, Inc. (MAZE) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$23.42

From 52W high−56.56%

Volume1.47M

Market cap$1.25B

P/E (TTM)—

P/S (TTM)62.5x

Div yield—

Key dataSep 18, 2026

Open

$23.42

From 52W high

−56.56%

Volume

1.47M

Market cap

$1.25B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.9x

P/E (TTM)

—

RSI (14)

24.7

MomentumView details →

1D Return

−3.92%

YTD Return

−46.58%

SummaryUpdated Jun 1, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in South San Francisco, California. Originally incorporated as Modulus Therapeutics, Inc., the company changed its name to Maze Therapeutics in September 2018. The company went public on January 31, 2025, representing one of the first biotechnology IPOs of the year. Maze focuses on developing precision medicines for serious diseases affecting the kidneys, cardiovascular system, and related metabolic conditions, with a particular emphasis on genetic-based therapeutic approaches.

Ask drillr about Maze Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−6.9x

EV/Sales

45.0x

P/S (TTM)

62.5x

P/B (TTM)

2.8x

ProfitabilityView details →

Gross Margin

95.28%

Net Margin

−667.95%

EBITDA Margin

−651.39%

ROE (TTM)

−29.48%

ROA (TTM)

−25.13%

Asset Turnover

0.04x

GrowthView details →

Revenue YoY

+700.00%

EPS YoY

−62.51%

FCF YoY

−0.20%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

—

EBITDA YoY

−10.79%

MomentumView details →

1D Return

−3.92%

YTD Return

−46.58%

1Y Return

−3.53%

RSI (14)

24.7

vs 50D SMA

−19.39%

vs 200D SMA

−34.27%

Capital & dividendView details →

Debt/Equity

0.13x

Current Ratio

18.31x

Quick Ratio

18.31x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.76

EPS Surprise

−5.95%

Beats (12Q)

2/12

Next Q EPS Est

−$0.76

Avg Surprise (4Q)

2.79%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

20.00M

Net Income (TTM)

−133.59M

Op. CF (TTM)

−106.54M

Next earningsNov 5, 2026 →

Latest newsMore news →

Maze Therapeutics, Inc. appointed Paula A. Johnson and Sophie Kornowski as Class III and Class I directors, respectively, effective August 13, 2026, each receiving an option to purchase 36,000 shares of the company's common stock.35d ago

Similar companies

ST嘉必优688089.SH NewAmsterdam Pharma Company N.V.NAMSW Vor Biopharma Inc.VOR Replimune Group, Inc.REPL MeiraGTx Holdings plcMGTX Aktis Oncology, Inc.AKTS Find similar companies →

Latest newsMore news →